Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the November 18, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without upfront costs through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must act by November 18, 2025, to serve as lead plaintiff, representing other class members in the litigation [3][6]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving over $438 million in recoveries for investors in 2019 alone [4]. Group 3: Allegations Against Jasper Therapeutics - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact the clinical and commercial prospects of its products, particularly briquilimab [5]. - The failure to disclose these issues allegedly led to inflated business and financial prospects, resulting in investor damages when the true information became public [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Jasper Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and compliance with cGMP regulations, which could negatively impact the clinical and commercial prospects of its products, including briquilimab [5]. - The failure to ensure proper manufacturing processes increased the risk of confounding study results, leading to overstated business and financial prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages due to the misleading public statements made by the defendants [5].

Core Points - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [7] Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [3] - The failure to disclose these issues allegedly increased the likelihood of disruptive cost-reduction measures and overstated the company's business and financial prospects [3] Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7] - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [7] About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Jasper Therapeutics, Inc. securities during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [1]. Group 1: Class Action Details - Investors who bought Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by November 18, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time, and has consistently ranked highly in securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Jasper Therapeutics made false or misleading statements regarding its manufacturing controls and compliance with regulations, which could negatively impact the prospects of its products, including briquilimab [5]. - The failure to ensure proper manufacturing processes increased the risk of confounding study results, potentially leading to disruptive cost-reduction measures and overstated business prospects [5]. - The lawsuit claims that when the true details became public, investors suffered damages due to the misleading statements made by the defendants [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper controls in manufacturing processes [3][5]. Group 1: Legal Investigation and Class Action - The firm is reminding investors of the November 18, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against Jasper [3]. - Investors who suffered losses in Jasper between November 30, 2023, and July 3, 2025, are encouraged to contact the firm to discuss their legal rights [1][3]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the commercial prospects of its products, including briquilimab [5]. - The failure to disclose these issues has led to overstated business and financial prospects for Jasper, making public statements materially false and misleading [5]. Group 3: Impact of Recent Developments - On July 7, 2025, Jasper reported issues with a drug product lot used in clinical trials, leading to a significant drop in stock price by $3.73 per share, or 55.1%, closing at $3.04 per share [6]. - The company announced a halt in the ETESIAN Study and paused development in asthma and SCID, alongside plans for cost-cutting measures and potential restructuring to extend its financial runway [6].

Core Points - Rosen Law Firm is reminding purchasers of Jasper Therapeutics, Inc. securities about the lead plaintiff deadline on November 18, 2025 for those who bought shares between November 30, 2023 and July 3, 2025 [1] Group 1 - The Class Period for Jasper Therapeutics securities is defined as between November 30, 2023 and July 3, 2025 [1] - Investors who purchased securities during this period may be entitled to compensation without any out-of-pocket fees or costs through a contingency fee arrangement [1]

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the class period from November 30, 2023, to July 3, 2025 [3][7]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact clinical trial results and the regulatory prospects of its products, particularly briquilimab [3]. - The failure to maintain proper controls increased the likelihood of cost-reduction measures and overstated the company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Jasper Therapeutics, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and lack of proper manufacturing controls [2][4]. Group 1: Legal Investigation - The firm is encouraging investors who suffered losses exceeding $75,000 in Jasper between November 30, 2023, and July 3, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Jasper, with a deadline of November 18, 2025, for investors to seek the role of lead plaintiff [2][6]. Group 2: Allegations Against Jasper - The complaint alleges that Jasper lacked necessary controls to ensure third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could confound study results and negatively impact product prospects [4]. - Specific issues were highlighted regarding the BEACON Study, where results were confounded by a problematic drug product lot, leading to a halt in development for certain studies and a need for cost-cutting measures [5]. Group 3: Financial Impact - Following the announcement of these issues, Jasper's stock price fell by $3.73 per share, or 55.1%, closing at $3.04 per share on July 7, 2025 [5].

Core Viewpoint - A class action lawsuit has been filed against Jasper Therapeutics, Inc. for allegedly making materially false and misleading statements regarding its business operations and compliance policies during the Class Period from November 30, 2023, to July 3, 2025 [3][8]. Allegation Details - The lawsuit claims that Jasper lacked necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations, which could negatively impact the results of ongoing studies and the regulatory and commercial prospects of its products, particularly briquilimab [3]. - The failure to maintain proper controls increased the likelihood of disruptive cost-reduction measures and overstated the company's business and financial prospects [3]. Next Steps - Investors who purchased Jasper shares and suffered losses are encouraged to contact the law firm for more information about their rights and potential claims [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 18, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Core Viewpoint - Jasper Therapeutics, a clinical-stage biotechnology company, is facing a class action lawsuit due to allegations of misleading investors about the commercial prospects of its lead product candidate, briquilimab [1][2]. Allegations - The lawsuit claims that Jasper failed to disclose critical information regarding its manufacturing processes, specifically that it lacked the necessary controls and procedures to ensure third-party manufacturers complied with cGMP regulations [2]. - This failure allegedly increased the risk of confounding results in ongoing studies, negatively impacting the regulatory and commercial prospects of the company's products, including briquilimab [2]. - The situation heightened the likelihood of disruptive cost-reduction measures, leading to an overstatement of the company's business and financial prospects, as well as briquilimab's clinical and commercial potential [2]. Stock Price Impact - Following the revelation of these issues on July 7, 2025, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decline, closing at $3.04 per share [3].